14th Jul 2015 09:01
LONDON (Alliance News) - Futura Medical PLC said Tuesday that headline clinical data from studies of its two non-steroidal anti-inflammatory products in pain relief are "very encouraging", although the study of a third product, SPR300, did not meet its primary endpoint.
The two non-steroidal anti-inflammatory products TPR100 and TIB200 both met all of their primary clinical endpoints, and Futura said the data provides a "clear pathway for the products' further development" and reinforces its expectation of their commercial potential.
Futura expects the final study report in September.
"Meeting our primary clinical endpoints for pain relief for our NSAID gel formulations in these headline results is a substantial achievement in terms of moving our goal of regulatory approval closer, as well as assisting the commercialisation of both products," said Chief Executive Officer James Barder in a statement.
"We intend to consult with regulators as soon as practicable to confirm the remaining requirements to obtain marketing authorisations for both products, as well as continue our dialogue with potential commercial licensees," Barder added.
Shares in Futura were down 2.7% at 36.00 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Futura Medical